Daily Sepsis Research Analysis
Three papers stand out today: a meta-analysis of 27 randomized trials shows ultrashort-acting beta-blockers significantly reduce 28-day mortality in sepsis; a massive propensity-matched cohort links baseline SGLT2 inhibitor use to lower risk of sepsis-induced cardiomyopathy and mortality; and an ICU cohort demonstrates that hyperinflammatory molecular subphenotypes are common and prognostically meaningful in immunocompromised sepsis, especially in hematologic malignancy.
Summary
Three papers stand out today: a meta-analysis of 27 randomized trials shows ultrashort-acting beta-blockers significantly reduce 28-day mortality in sepsis; a massive propensity-matched cohort links baseline SGLT2 inhibitor use to lower risk of sepsis-induced cardiomyopathy and mortality; and an ICU cohort demonstrates that hyperinflammatory molecular subphenotypes are common and prognostically meaningful in immunocompromised sepsis, especially in hematologic malignancy.
Research Themes
- Targeted hemodynamic modulation in sepsis
- Cardiometabolic therapies and sepsis-induced cardiomyopathy prevention
- Precision medicine via inflammatory subphenotyping in immunocompromised sepsis
Selected Articles
1. Effect of ultrashort-acting β-blocker on the mortality of patients with sepsis or septic shock: A systematic review and trial sequential meta-analysis of randomized controlled trials.
Across 27 randomized trials (n=2253), ultrashort-acting beta-blockers significantly reduced 28-day mortality (RR 0.66, 95% CI 0.56–0.78). Trial sequential analysis supported robustness, with benefits notable in septic tachycardia, septic cardiomyopathy, and with esmolol use.
Impact: This synthesis of RCTs with TSA provides high-level evidence that beta-blockade improves survival in sepsis, a potential practice-changing finding if validated in guideline-directed care pathways.
Clinical Implications: Consider esmolol or landiolol as adjuncts for septic tachycardia under hemodynamic monitoring, with protocols emphasizing patient selection (e.g., persistent tachycardia), titration, and safety surveillance.
Key Findings
- Pooled 28-day mortality reduction with ultrashort-acting beta-blockers (RR 0.66; 95% CI 0.56–0.78).
- Trial sequential analysis confirmed sufficient information size for mortality benefit.
- Benefits persisted in subgroups: septic tachycardia (RR 0.66), septic cardiomyopathy (RR 0.61), Chinese cohorts, and esmolol-treated patients.
- Mortality benefit in septic shock was significant only in patients with tachycardia.
Methodological Strengths
- Inclusion of only randomized controlled trials with comprehensive database search
- Trial sequential analysis to assess robustness and control random errors
Limitations
- Heterogeneity in populations, dosing strategies, and co-interventions across trials
- Potential geographic concentration (e.g., many trials from China) limiting generalizability
Future Directions: Large pragmatic multicenter RCTs with standardized protocols and hemodynamic targets to define indications, dosing, and safety in diverse sepsis populations.
BACKGROUND: Adrenergic responses, particularly tachycardia, play a role in sepsis-related complications. Ultrashort-acting β-blockers have been evaluated in randomized controlled trials (RCTs) for their impact on sepsis outcomes, but conflicting results have been reported. This systematic review and meta-analysis aim to provide an updated perspective on the impact of ultrashort-acting β-blockers on the clinical outcomes of sepsis. METHODS: A comprehensive search of PubMed, Embase, Cochrane Library, China Nati
2. Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study.
In 73,069 propensity-matched patients per group, baseline SGLT2 inhibitor use versus DPP4 inhibitors was associated with lower risk of SICM (HR 0.78), all-cause mortality (HR 0.58), hospitalization (HR 0.83), and MACEs (HR 0.86). Subgroup and negative control analyses supported robustness.
Impact: Identifies a widely available cardiometabolic therapy potentially mitigating sepsis-induced cardiac dysfunction and mortality, offering a testable preventive strategy.
Clinical Implications: For patients with T2D at risk of infection, continued SGLT2 inhibitor therapy may confer cardioprotective benefits if not contraindicated; however, initiation during acute sepsis is unproven and requires caution (e.g., monitor for euglycemic ketoacidosis and volume status).
Key Findings
- Baseline SGLT2 inhibitor use lowered SICM risk vs DPP4 inhibitors (HR 0.78; 95% CI 0.71–0.86).
- Significant reductions in 1-year all-cause mortality (HR 0.58; 95% CI 0.55–0.62), hospitalization (HR 0.83), and MACEs (HR 0.86).
- Findings consistent across subgroups; negative control outcomes supported robustness.
Methodological Strengths
- Very large real-world dataset with 1:1 propensity score matching
- Robustness checks including subgroup analyses and negative control outcomes
Limitations
- Observational design with potential residual confounding and exposure misclassification
- Generalizability limited to patients with type 2 diabetes and prior drug exposure
Future Directions: Prospective trials to test peri-infectious continuation or initiation strategies of SGLT2 inhibitors and mechanistic studies on SICM modulation.
AIM: Sepsis-induced cardiomyopathy (SICM) is a transient cardiac dysfunction that occurs in a substantial proportion of patients with sepsis and is associated with poor prognosis. However, preventive strategies remain limited. This study aimed to assess whether baseline use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) compared to dipeptidyl peptidase-4 inhibitors (DPP4is) is associated with a reduced risk of SICM in patients with type 2 diabetes mellitus (T2D) and sepsis. METHODS: Usi
3. Prognostic Relevance of Inflammatory Subphenotypes in Immunocompromised Patients With Sepsis.
In two ICU sepsis cohorts (n=1826), hematologic malignancy was strongly associated with the hyperinflammatory subphenotype (OR 4.3; p<0.0001), an effect robust to adjustments. Hyperinflammatory classification predicted poorer survival in hematologic malignancy but not in solid organ transplant or solid tumor chemotherapy.
Impact: Extends sepsis subphenotyping into immunocompromised populations, revealing condition-specific prognostic value that can guide precision trial design and tailored therapies.
Clinical Implications: Inflammatory subphenotyping may refine risk stratification and therapeutic targeting in immunocompromised sepsis, particularly for patients with hematologic malignancy who display hyperinflammatory biology.
Key Findings
- Hematologic malignancy strongly associated with hyperinflammatory subphenotype (OR 4.3; p<0.0001), robust to adjustments for pathogen, bacteremia, and illness severity.
- Solid organ transplant associated with hyperinflammatory subphenotype (OR 1.6; p=0.02) but not after accounting for bacteremia.
- Hyperinflammatory classification predicted decreased survival in hematologic malignancy, but not in transplant or solid malignancy populations.
Methodological Strengths
- Two independent ICU cohorts with predefined latent class-derived subphenotypes
- Multivariable logistic regression and survival analyses with relevant clinical adjustments
Limitations
- Observational design limits causal inference and potential residual confounding
- Generalizability may vary across immunocompromised conditions and centers
Future Directions: Prospective validation and integration of subphenotypes into adaptive trials targeting immunocompromised subgroups, exploring differential treatment responses.
OBJECTIVES: Hyperinflammatory and hypoinflammatory molecular subphenotypes in sepsis and acute respiratory distress syndrome have divergent mortality and treatment responses in secondary analyses of randomized controlled trials. However, the prevalence of immunocompromise is low in these populations, and how preexisting immunocompromise contributes to subphenotypes is unknown. We studied two observational sepsis cohorts to test associations between immunocompromise and the hyperinflammatory subp